Sickle Cell Disease Treatment Market Share Forecast - 2032

Sickle Cell Disease Treatment Market - By Treatment Modality [Blood Transfusion, Pharmacotherapy (Hydroxyurea, Oxybryta, Endari), Bone Marrow Transplant], By Disease (Sickle Cell Anemia, Hemoglobin Sickle C), By End-user & Forecast, 2023-2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market definitions

1.2&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.3&nbsp;&nbsp;&nbsp; Forecast calculations

1.4&nbsp;&nbsp;&nbsp; Data sources

1.4.1&nbsp;&nbsp;&nbsp; Secondary

1.4.1.1&nbsp;&nbsp;&nbsp;Paid sources

1.4.1.2&nbsp;&nbsp;&nbsp;Public sources

1.4.2&nbsp;&nbsp;&nbsp; Primary

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Sickle cell disease treatment industry 3600 synopsis, 2018 &ndash; 2032 (USD Million)

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Region trends

2.1.3&nbsp;&nbsp;&nbsp; Treatment modality trends

2.1.4&nbsp;&nbsp;&nbsp; Disease type trends

2.1.5&nbsp;&nbsp;&nbsp; End-user trends

Chapter 3&nbsp;&nbsp;&nbsp;Sickle Cell disease Treatment Market Insights

3.1&nbsp;&nbsp;&nbsp; Industry landscape, 2018 &ndash; 2032 (USD Million)

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increasing prevalence of sickle cell disease

3.2.1.2&nbsp;&nbsp;&nbsp;Increasing R&amp;D activities in drug development for sickle cell disease

3.2.1.3&nbsp;&nbsp;&nbsp;Increasing healthcare expenditure and government initiatives

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High cost associated with the treatment

3.2.2.2&nbsp;&nbsp;&nbsp;Side effects associated with sickle cell disease treatment drugs

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By treatment modality

3.3.2&nbsp;&nbsp;&nbsp; By disease type

3.3.3&nbsp;&nbsp;&nbsp; By end-user

3.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Clinical trial analysis

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.7&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Global company market share analysis, 2022

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix, 2022

4.5&nbsp;&nbsp;&nbsp; Strategic dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Sickle Cell Disease Treatment Market Estimates and Forecast, By Treatment Modality (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by treatment modality

5.2&nbsp;&nbsp;&nbsp; Blood transfusion

5.3&nbsp;&nbsp;&nbsp; Pharmacotherapy

5.3.1&nbsp;&nbsp;&nbsp; By drug type

5.3.1.1&nbsp;&nbsp;&nbsp;Hydroxyurea

5.3.1.2&nbsp;&nbsp;&nbsp;Oxybryta

5.3.1.3&nbsp;&nbsp;&nbsp;Adakveo

5.3.1.4&nbsp;&nbsp;&nbsp;Endari

5.3.1.5&nbsp;&nbsp;&nbsp;Other pharmacotherapies

5.3.2&nbsp;&nbsp;&nbsp; By route of administration

5.3.2.1&nbsp;&nbsp;&nbsp;Oral

5.3.2.2&nbsp;&nbsp;&nbsp;Parenteral

5.4&nbsp;&nbsp;&nbsp; Bone marrow transplant

Chapter 6&nbsp;&nbsp;&nbsp;Sickle Cell Disease Treatment Market Estimates and Forecast, By Disease Type (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by disease type

6.2&nbsp;&nbsp;&nbsp; Sickle cell anemia

6.3&nbsp;&nbsp;&nbsp; Hemoglobin sickle C disease (HbSC)

6.4&nbsp;&nbsp;&nbsp; Other disease types

Chapter 7&nbsp;&nbsp;&nbsp;Sickle Cell Disease Treatment Market Estimates and Forecast, By End-user (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by end-user

7.2&nbsp;&nbsp;&nbsp; Hospitals

7.3&nbsp;&nbsp;&nbsp; Specialty clinics

7.4&nbsp;&nbsp;&nbsp; Other end-users

Chapter 8&nbsp;&nbsp;&nbsp;Sickle Cell Disease Treatment Market Estimates and Forecast, By Region (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by region

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Switzerland

8.3.7&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; China

8.4.2&nbsp;&nbsp;&nbsp; Japan

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; Rest of MEA

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Pfizer, Inc.

9.2&nbsp;&nbsp;&nbsp; Novartis AG

9.3&nbsp;&nbsp;&nbsp; Emmaus Medical, Inc.

9.4&nbsp;&nbsp;&nbsp; Medunik USA, Inc.

9.5&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company

9.6&nbsp;&nbsp;&nbsp; Bluebird Bio, Inc.

9.7&nbsp;&nbsp;&nbsp; Agios Pharmaceuticals

9.8&nbsp;&nbsp;&nbsp; CRISPR Therapeutics

9.9&nbsp;&nbsp;&nbsp; Vifor Pharma

9.10&nbsp;&nbsp;&nbsp; Editas Medicine Inc. 
&nbsp;

Sickle Cell Disease Treatment Market

Inquiry Before Buying